EP3303401A4 - Traitement du cancer par manipulation de la flore microbienne commensale - Google Patents

Traitement du cancer par manipulation de la flore microbienne commensale Download PDF

Info

Publication number
EP3303401A4
EP3303401A4 EP16804316.4A EP16804316A EP3303401A4 EP 3303401 A4 EP3303401 A4 EP 3303401A4 EP 16804316 A EP16804316 A EP 16804316A EP 3303401 A4 EP3303401 A4 EP 3303401A4
Authority
EP
European Patent Office
Prior art keywords
manipulation
cancer
treatment
commensal microflora
commensal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16804316.4A
Other languages
German (de)
English (en)
Other versions
EP3303401B1 (fr
EP3303401C0 (fr
EP3303401A1 (fr
Inventor
Thomas F. Gajewski
Ayelet SIVAN
Leticia CORRALES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57441608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3303401(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Chicago filed Critical University of Chicago
Priority to EP24199298.1A priority Critical patent/EP4541361A3/fr
Publication of EP3303401A1 publication Critical patent/EP3303401A1/fr
Publication of EP3303401A4 publication Critical patent/EP3303401A4/fr
Application granted granted Critical
Publication of EP3303401B1 publication Critical patent/EP3303401B1/fr
Publication of EP3303401C0 publication Critical patent/EP3303401C0/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP16804316.4A 2015-06-01 2016-06-01 Traitement du cancer par manipulation de la flore microbienne commensale Active EP3303401B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24199298.1A EP4541361A3 (fr) 2015-06-01 2016-06-01 Traitement du cancer par manipulation de la microflore commensale

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562169112P 2015-06-01 2015-06-01
US201562248741P 2015-10-30 2015-10-30
PCT/US2016/035228 WO2016196605A1 (fr) 2015-06-01 2016-06-01 Traitement du cancer par manipulation de la flore microbienne commensale

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP24199298.1A Division EP4541361A3 (fr) 2015-06-01 2016-06-01 Traitement du cancer par manipulation de la microflore commensale
EP24199298.1A Division-Into EP4541361A3 (fr) 2015-06-01 2016-06-01 Traitement du cancer par manipulation de la microflore commensale

Publications (4)

Publication Number Publication Date
EP3303401A1 EP3303401A1 (fr) 2018-04-11
EP3303401A4 true EP3303401A4 (fr) 2018-12-26
EP3303401B1 EP3303401B1 (fr) 2024-10-16
EP3303401C0 EP3303401C0 (fr) 2024-10-16

Family

ID=57441608

Family Applications (2)

Application Number Title Priority Date Filing Date
EP24199298.1A Pending EP4541361A3 (fr) 2015-06-01 2016-06-01 Traitement du cancer par manipulation de la microflore commensale
EP16804316.4A Active EP3303401B1 (fr) 2015-06-01 2016-06-01 Traitement du cancer par manipulation de la flore microbienne commensale

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP24199298.1A Pending EP4541361A3 (fr) 2015-06-01 2016-06-01 Traitement du cancer par manipulation de la microflore commensale

Country Status (18)

Country Link
US (4) US9855302B2 (fr)
EP (2) EP4541361A3 (fr)
JP (2) JP2018521013A (fr)
KR (2) KR102661603B1 (fr)
CN (1) CN107847530A (fr)
AU (1) AU2016270750B2 (fr)
BR (1) BR112017025813A2 (fr)
CA (1) CA2987129A1 (fr)
CL (1) CL2017003024A1 (fr)
HK (1) HK1253064A1 (fr)
IL (1) IL255940A (fr)
MX (1) MX2017015473A (fr)
PE (1) PE20180673A1 (fr)
RU (1) RU2017141448A (fr)
TW (1) TW201717975A (fr)
UY (1) UY36701A (fr)
WO (1) WO2016196605A1 (fr)
ZA (2) ZA201707986B (fr)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3564357T3 (da) 2010-02-01 2022-06-20 Rebiotix Inc Bakterieterapi mod clostridium difficile colitis
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CA2889182A1 (fr) * 2012-10-26 2014-05-01 The University Of Chicago Combinaison synergique d'inhibiteurs immunologiques pour le traitement du cancer
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
EP3400953A1 (fr) 2014-12-23 2018-11-14 4D Pharma Research Limited Polypeptide pirin et modulation immunitaire
AR103260A1 (es) 2014-12-23 2017-04-26 4D Pharma Res Ltd Modulación inmunitaria
EP3711488A1 (fr) 2015-05-06 2020-09-23 Snipr Technologies Limited Modification de populations microbiennes et de microbiotes
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
NZ737752A (en) 2015-06-15 2022-02-25 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SMT201900588T1 (it) 2015-06-15 2019-11-13 4D Pharma Res Limited Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2016203221A1 (fr) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprenant des souches bactériennes
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
FR3045383B1 (fr) 2015-12-18 2019-06-14 Maat Pharma Procede de lyophilisation d'un echantillon de microbiote fecal
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
ME03487B (fr) 2016-03-04 2020-01-20 4D Pharma Plc Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
KR102708641B1 (ko) 2016-09-27 2024-09-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 미생물유전체를 조정함으로써 면역 체크포인트 차단 요법을 증강시키는 방법
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
EP3554521A4 (fr) 2016-12-15 2020-09-16 The Regents of The University of California Composition orale contenant des bactéries d'acide lactique pour réguler des réactions immunitaires et méthodes associées
EP3559257A1 (fr) * 2016-12-22 2019-10-30 Institut Gustave Roussy (IGR) Composition de microbiote, à titre de marqueur de réactivité à des anticorps anti-pd1/pd-l1/pd-l2 et utilisation de modulateurs microbiens pour améliorer l'efficacité d'un traitement à base d'anticorps anti-pd1/pd-l1/pd-l2
RU2761873C2 (ru) * 2016-12-23 2021-12-13 Кэйо Юниверсити Композиции и способы для индукции cd8+ t-клеток
US11666646B2 (en) 2016-12-26 2023-06-06 National University Corporation Kobe University Cancer therapy utilizing combination of oral tumor vaccine and immunosuppression inhibitor
EP3570856A2 (fr) * 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Méthodes de traitement du cancer
US11723935B2 (en) * 2017-02-06 2023-08-15 New York University Methods and compositions for treating and diagnosing pancreatic cancers
WO2018171555A1 (fr) * 2017-03-20 2018-09-27 Crown Bioscience Inc. (Taicang) Utilisation d'une composition de microbiote intestinal en immunothérapie
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
EP3630942B1 (fr) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprenant des souches bactériennes
US11638728B2 (en) 2017-06-05 2023-05-02 The University Of Chicago Microbiome biomarkers immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof
SMT202000555T1 (it) 2017-06-14 2020-11-10 4D Pharma Res Limited Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
CA3066189A1 (fr) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprenant des souches bacteriennes
TW201906620A (zh) 2017-07-05 2019-02-16 美商艾弗洛生物科技股份有限公司 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法
MX2020000903A (es) * 2017-08-11 2020-07-22 Genentech Inc Anticuerpos anti-cd8 y usos de los mismos.
US20190175560A1 (en) * 2017-12-01 2019-06-13 Shepherd Therapeutics, Inc. Mebendazole cancer therapies and methods of use
US20210060038A1 (en) * 2018-01-17 2021-03-04 Reponex Pharmaceuticals A/S Compositions for eliminating bacterial promotors of colorectal cancer by intraluminal application
JP2021510688A (ja) * 2018-01-19 2021-04-30 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ がんを処置または予防するための併用療法
MX2020007665A (es) * 2018-01-19 2020-09-14 4D Pharma Res Limited Terapia de combinacion para tratar o prevenir el cancer.
JP2021516216A (ja) * 2018-01-19 2021-07-01 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ がんを処置または予防するための併用療法
BR112020014565A2 (pt) * 2018-01-19 2020-12-08 4D Pharma Research Limited Terapia de combinação para tratamento ou prevenção de câncer
CN110090230B (zh) * 2018-01-30 2022-07-12 青岛东海药业有限公司 凝结芽孢杆菌在制备预防或治疗胆管癌制剂中的应用
WO2019149859A1 (fr) * 2018-01-31 2019-08-08 Universität Basel Bactéries commensales intestinales pour le traitement du cancer colorectal humain
AU2019217041B2 (en) * 2018-02-09 2022-09-15 Keio University Compositions and methods for the induction of CD8+ T-cells
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
EP3773915A2 (fr) * 2018-03-28 2021-02-17 Seres Therapeutics, Inc. Traitement d'un cancer par modulation du microbiome
KR101980525B1 (ko) * 2018-04-12 2019-05-21 주식회사 지놈앤컴퍼니 락토코커스 락티스 gen3013 균주, 및 이를 포함하는 암의 예방 또는 치료용 조성물
US20220010267A1 (en) * 2018-05-30 2022-01-13 Evolve Biosystems, Inc. Compostions and method of use for h5 competent bifidobacterium longum subsp. infantis
WO2019240218A1 (fr) 2018-06-14 2019-12-19 株式会社明治 Composition pour favoriser une thérapie d'inhibition de points de contrôle immunitaires
CN112703005A (zh) * 2018-07-17 2021-04-23 费灵有限公司 包括微生物群恢复治疗（mrt）组合物的联合疗法
EP3597202A1 (fr) * 2018-07-20 2020-01-22 Maat Pharma Composition du microbiote fécal destinée à être utilisée pour réduire l'inflammation induite par traitement
AU2019317986A1 (en) * 2018-08-05 2021-02-11 Da Volterra Method for improving anticancer agent efficacy
WO2020055547A2 (fr) 2018-08-18 2020-03-19 Seed Health, Inc. Procédés et compositions pour la santé d'abeilles mellifères
EP3858368B1 (fr) 2018-09-25 2023-11-29 National Cerebral and Cardiovascular Center Potentialisateur d'effet anticancéreux
CN109266766B (zh) * 2018-10-10 2021-10-19 中国人民解放军第三0二医院 肠道微生物作为胆管细胞癌诊断标志物的用途
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
US12551515B2 (en) 2018-11-21 2026-02-17 Board Of Regents Of The University Of Texas System Methods and compositions for treating cancer
KR102136772B1 (ko) * 2018-12-10 2020-07-23 한국식품연구원 락토바실러스 사케아이 wikim30을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
KR102069622B1 (ko) * 2019-06-25 2020-01-23 한국식품연구원 락토바실러스 퍼멘텀 WiKim0102를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
WO2020122476A1 (fr) * 2018-12-10 2020-06-18 한국식품연구원 Composition pharmaceutique comprenant un lactobacillus sakei wikim30 comme principe actif pour la prévention ou le traitement d'un cancer
CN110106104B (zh) * 2019-03-19 2021-12-17 江南大学 假小链双歧杆菌ccfm1048、其组合物、发酵食品、用途、菌剂及其菌剂制备方法
IL265735A (en) 2019-03-31 2019-05-30 Biomica A microbial consortium and its uses
CN111773377B (zh) * 2019-04-04 2023-03-14 中南大学 阿尼芬净在制备抗肿瘤药物中的应用及抗肿瘤药物
CN110063970B (zh) * 2019-04-30 2024-09-03 上海心脉途医疗科技有限公司 与irAE相关的肠道菌群及irAE的治疗和预防方法
CN111991427A (zh) * 2019-05-07 2020-11-27 瑞微（深圳）生物科技有限公司 肠道细菌在制备用于促进TCR γδ+T细胞增殖的药物中的应用
CN110734888B (zh) * 2019-09-17 2021-08-03 广州维生君生物科技有限公司 Tim3人源单链抗体融合基因转化乳酸菌及其应用
US20240181049A1 (en) * 2019-11-01 2024-06-06 Uti Limited Partnership Harnessing the power of microbiota and metabolites for the treatment of cancer
WO2021127235A1 (fr) 2019-12-20 2021-06-24 Persephone Biosciences, Inc. Compositions pour moduler des populations de microflore intestinale, améliorer l'efficacité de médicaments et traiter le cancer, et procédés de fabrication de celles-ci et utilisation de celles-ci
WO2021146647A1 (fr) * 2020-01-17 2021-07-22 Second Genome, Inc. Méthodes et compositions pour le traitement du cancer
CN118340799A (zh) * 2020-02-27 2024-07-16 上海上药信谊药厂有限公司 抗肿瘤组合物
CN111096982B (zh) * 2020-02-27 2023-09-12 上海上药信谊药厂有限公司 抗肿瘤组合物
US20220120746A1 (en) * 2020-03-18 2022-04-21 Sabine Hazan Methods of Determining Susceptibility to COVID-19 Infection
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
GB202007452D0 (en) 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
NL2025863B1 (en) 2020-06-19 2022-02-17 Acad Medisch Ct Fecal matter for treatment of cachexia
KR102351601B1 (ko) 2020-07-06 2022-01-13 연세대학교 산학협력단 장내 미생물 기반 면역 항암 요법의 치료 반응 예측과 향상 방법 및 후보 프리바이오틱스 스크리닝 방법
KR20220028425A (ko) 2020-08-28 2022-03-08 주식회사 리비옴 항종양 세균 균주, 및 이를 이용한 조성물 및 방법
EP4206317A4 (fr) 2020-08-28 2024-11-20 LIVEOME Inc. Souche bactérienne antitumorale et composition et méthode la mettant en ?uvre
KR102489493B1 (ko) * 2020-08-31 2023-01-18 주식회사 리비옴 항암 활성을 갖는 락토바실러스 플란타룸 미생물, 그를 포함하는 조성물 및 그를 이용한 암 예방 또는 치료 방법
JP2023550544A (ja) 2020-11-03 2023-12-01 アールディスカバリー エルエルシー がんおよびファゴサイトーシス不全に関連する疾患の処置のための療法
KR102307603B1 (ko) * 2020-11-13 2021-10-05 주식회사 비피도 비피도박테리움 롱검 rapo (kctc13773bp)를 포함하는 암 예방 또는 치료용 조성물
WO2022261382A1 (fr) * 2021-06-09 2022-12-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions et méthodes pour déterminer la réactivité à des inhibiteurs du point de contrôle immunitaire (ici), pour augmenter l'efficacité d'ici et pour traiter le cancer
JP2024534805A (ja) * 2021-08-17 2024-09-26 フォンダツィオーネ ペル リスティトゥート オンコロジコ ディ リチェルカ （イオエッレ） 共生細菌は前立腺がんにおいてアンドロゲン生合成を介して内分泌抵抗性を促進する
CN115786156A (zh) * 2021-09-10 2023-03-14 香港中文大学 用于结直肠肿瘤的预防、治疗或风险控制的组合物
WO2023118868A1 (fr) * 2021-12-21 2023-06-29 Quadram Institute Bioscience Bifidobacterium et ses compositions pour le traitement du cancer du sein
CN114344342B (zh) * 2021-12-29 2023-06-30 广东南芯医疗科技有限公司 副干酪乳杆菌Lp. R3在制备预防或治疗肿瘤药物中的应用
EP4465997A4 (fr) * 2022-01-18 2026-02-18 Univ California Compositions bactériennes et méthodes de traitement du cancer et de maladies immunitaires
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024035638A1 (fr) * 2022-08-08 2024-02-15 Cornell University Procédés de classification et de traitement des tumeurs gastro-intestinales fondés sur l'analyse du mycobiome
IT202200022401A1 (it) * 2022-10-31 2024-05-01 Probionova Sa Ceppi di batteri per il trattamento di disturbi urologici, loro composizioni e usi relativi
CN117089490B (zh) * 2023-08-11 2024-06-07 浙江大学 青春双歧杆菌basj001及应用
WO2025176152A1 (fr) * 2024-02-19 2025-08-28 The University Of Hong Kong Mélanges probiotiques et leurs procédés d'utilisation pour le traitement de cancers
CN118001305B (zh) * 2024-04-09 2024-06-11 山东中科嘉亿生物工程有限公司 长双歧杆菌jblc-141在制备改善副肿瘤性血小板增多症药物中的应用
WO2026011048A1 (fr) * 2024-07-03 2026-01-08 Ohio State Innovation Foundation Antigène bactérien commensal utilisé en tant qu'agent thérapeutique contre les cancers
CN121550264B (zh) * 2026-01-26 2026-04-17 华中科技大学同济医学院附属协和医院 一种基于呼吸道共生菌的抗肿瘤制剂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2876167A1 (fr) * 2013-11-21 2015-05-27 Institut Gustave Roussy Composition de la flore microbienne, comme marqueur de la réceptivité à la chimiothérapie et utilisation de modulateurs microbiens (pré-, pro- ou synbiotiques) pour améliorer l'efficacité d'un traitement du cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
JP2005089388A (ja) * 2003-09-18 2005-04-07 Biofuerumin Seiyaku Kk 免疫賦活作用増強剤
GB0323039D0 (en) * 2003-10-01 2003-11-05 Danisco Method
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
TW200819540A (en) * 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US8444967B2 (en) 2010-07-09 2013-05-21 Master Supplements, Inc. Treatment including prebiotic composition for use with probiotics
DE102008045815A1 (de) * 2008-09-05 2010-03-11 Universität Rostock Kombination aus mindestens einem Antikörper und einem Bakterium, welches Fc-Rezeptoren oder die leichte Kette eines Antikörpers bindendende Proteine exprimiert
EP2498789B1 (fr) * 2009-11-11 2016-06-22 Alimentary Health Limited Souche de bifidobacterium probiotique
WO2011066342A2 (fr) * 2009-11-24 2011-06-03 Amplimmune, Inc. Inhibition simultanée de pd-l1/pd-l2
EP3318248B1 (fr) * 2009-12-01 2019-04-10 Translate Bio, Inc. Administration d'arnm pour l'augmentation des protéines et des enzymes dans des maladies génétiques humaines
WO2014145958A2 (fr) 2013-03-15 2014-09-18 Seres Health, Inc. Compositions microbiennes et procédés associés basés sur un réseau
CN104415060A (zh) * 2013-08-30 2015-03-18 深圳华大基因科技有限公司 可食用组合物及其制备方法和用途
EP3060654B1 (fr) * 2013-10-21 2023-03-15 Hemoshear, LLC Modèle in vitro pour micro-environnement tumoral
IL292510A (en) * 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
WO2015176033A1 (fr) * 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Traitement du cancer du poumon à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un autre agent anticancéreux
WO2016063263A2 (fr) 2014-10-23 2016-04-28 Institut Gustave Roussy Procédés et produits permettant de moduler la composition du microbiote afin d'améliorer l'efficacité d'un traitement anticancéreux impliquant un inhibiteur des points de contrôle du système immunitaire
TW201906620A (zh) * 2017-07-05 2019-02-16 美商艾弗洛生物科技股份有限公司 使用動物雙岐桿菌乳亞種 (bifidobacterium animalis ssp. lactis) 治療癌症之組合物及方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2876167A1 (fr) * 2013-11-21 2015-05-27 Institut Gustave Roussy Composition de la flore microbienne, comme marqueur de la réceptivité à la chimiothérapie et utilisation de modulateurs microbiens (pré-, pro- ou synbiotiques) pour améliorer l'efficacité d'un traitement du cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
A. SIVAN ET AL: "Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy", SCIENCE, vol. 350, no. 6264, 27 November 2015 (2015-11-27), pages 1084 - 1089, XP055310361, ISSN: 0036-8075, DOI: 10.1126/science.aac4255 *
DOMENICA REA ET AL: "Microbiota effects on cancer: from risks to therapies", ONCOTARGET, vol. 9, no. 25, 2 April 2018 (2018-04-02), pages 17915 - 17927, XP055522164, DOI: 10.18632/oncotarget.24681 *
LOPEZ P ET AL: "Distinct Bifidobacterium strains drive different immune responses in vitro", INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, ELSEVIER BV, NL, vol. 138, no. 1-2, 31 March 2010 (2010-03-31), pages 157 - 165, XP026920572, ISSN: 0168-1605, [retrieved on 20100104], DOI: 10.1016/J.IJFOODMICRO.2009.12.023 *
MARK ZIPKIN ET AL: "Microbiome at the checkpoint", BC INNOVATIONS, COVER STORY, 3 December 2015 (2015-12-03), United States, XP055522712, Retrieved from the Internet <URL:https://evelobio.com/wp-content/uploads/2018/03/CTLA-4andPD-L1blockadedependsonspecificcommensalbacteria-BioCentury.com1_.pdf> [retrieved on 20181112] *
MENARD O ET AL: "Gnotobiotic mouse immune response induced by Bifidobacterium sp. strains isolated from infants", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 3, 1 February 2008 (2008-02-01), pages 660 - 666, XP002573761, ISSN: 0099-2240, [retrieved on 20071214], DOI: 10.1128/AEM.01261-07 *
PING DONG ET AL: "The role of intestinal bifidobacteria on immune system development in young rats", EARLY HUMAN DEVELOPMENT, vol. 86, no. 1, 1 January 2010 (2010-01-01), IR, pages 51 - 58, XP055522699, ISSN: 0378-3782, DOI: 10.1016/j.earlhumdev.2010.01.002 *
S VIAUD ET AL: "Gut microbiome and anticancer immune response: really hot Sh*t!", CELL DEATH AND DIFFERENTIATION., vol. 22, no. 2, 16 May 2014 (2014-05-16), GB, pages 199 - 214, XP055227164, ISSN: 1350-9047, DOI: 10.1038/cdd.2014.56 *
See also references of WO2016196605A1 *
SOPHIE VIAUD ET AL: "Why should we need the gut microbiota to respond to cancer therapies?", ONCOIMMUNOLOGY, vol. 3, no. 1, 1 January 2014 (2014-01-01), pages e27574, XP055169892, DOI: 10.4161/onci.27574 *

Also Published As

Publication number Publication date
WO2016196605A1 (fr) 2016-12-08
UY36701A (es) 2016-12-30
EP4541361A3 (fr) 2025-07-30
EP3303401B1 (fr) 2024-10-16
ZA201907641B (en) 2021-05-26
US20180015131A1 (en) 2018-01-18
EP3303401C0 (fr) 2024-10-16
TW201717975A (zh) 2017-06-01
AU2016270750A1 (en) 2017-12-14
EP4541361A2 (fr) 2025-04-23
KR102661603B1 (ko) 2024-04-29
PE20180673A1 (es) 2018-04-19
CA2987129A1 (fr) 2016-12-08
IL255940A (en) 2018-01-31
RU2017141448A (ru) 2019-07-15
MX2017015473A (es) 2018-08-15
ZA201707986B (en) 2020-01-29
US9855302B2 (en) 2018-01-02
CL2017003024A1 (es) 2018-07-06
EP3303401A1 (fr) 2018-04-11
AU2016270750B2 (en) 2022-06-16
US20220296656A1 (en) 2022-09-22
JP2022000447A (ja) 2022-01-04
CN107847530A (zh) 2018-03-27
BR112017025813A2 (pt) 2018-08-14
KR20180011262A (ko) 2018-01-31
HK1253064A1 (zh) 2019-06-06
JP2018521013A (ja) 2018-08-02
RU2017141448A3 (fr) 2019-11-19
US20160354416A1 (en) 2016-12-08
KR20240059639A (ko) 2024-05-07
US20190183942A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
ZA201907641B (en) Treatment of cancer by manipulation of commensal microflora
EP3630089A4 (fr) Méthodes de traitement du cancer
EP3393475A4 (fr) Méthodes de traitement du cancer
HUE055433T2 (hu) Kombinált készítmény rák kezelésére
IL259996A (en) Combinations for cancer treatment
EP3134436A4 (fr) Traitement de tumeurs provoquées par h-ras
EP3548028A4 (fr) Traitement du cancer
EP3157336A4 (fr) Oxabicycloheptanes et oxabicycloheptènes pour le traitement du cancer des ovaires
EP3177308A4 (fr) Utilisation de peptides qui bloquent l&#39;interaction métadhérine-snd1 pour le traitement du cancer
EP3119390A4 (fr) Méthodes de traitement du cancer
IL263835A (en) Exosome-guided treatment of cancer
EP3548007A4 (fr) Méthodes de traitement du cancer
EP3185910A4 (fr) Méthodes et compositions pour le traitement du cancer
ZA201707024B (en) Cancer treatment composition
EP3487999A4 (fr) Procédés de traitement d&#39;un cancer
EP3125937A4 (fr) Traitement du cancer gastrique
EP3389670A4 (fr) Méthodes de traitement du cancer du sein
EP3592357A4 (fr) Méthodes de traitement du cancer
EP3242681B8 (fr) Nouveaux composés pour le traitement du cancer
IL255167A0 (en) Compounds for the treatment of cancer
EP3270898A4 (fr) Procédés de traitement de cancer de la vessie
HK40015431A (en) Treatment of cancer
HK40032563A (en) Methods of treating cancer
HK40016485A (en) Methods of treating cancer
HK40016069A (en) Calreticulin-mediated cancer treatment

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CORRALES, LETICIA

Inventor name: GAJEWSKI, THOMAS F.

Inventor name: SIVAN, AYELET

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181122

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/39 20060101ALI20181116BHEP

Ipc: A61K 35/74 20150101ALI20181116BHEP

Ipc: C12Q 1/68 20180101ALI20181116BHEP

Ipc: C07K 16/28 20060101AFI20181116BHEP

Ipc: C07K 14/00 20060101ALI20181116BHEP

Ipc: C07H 21/02 20060101ALI20181116BHEP

Ipc: C07K 16/00 20060101ALI20181116BHEP

Ipc: A61P 35/00 20060101ALI20181116BHEP

Ipc: C12N 1/20 20060101ALI20181116BHEP

Ipc: A61K 35/745 20150101ALI20181116BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1253064

Country of ref document: HK

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220617

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240216

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE UNIVERSITY OF CHICAGO

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016089874

Country of ref document: DE

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20241025

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20241107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241016

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250116

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 10

Effective date: 20250509

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241016

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250501

Year of fee payment: 10

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241016

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241016

26 Opposition filed

Opponent name: HGF LIMITED

Effective date: 20250716

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250701

Year of fee payment: 10

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1253064

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250601